Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept
Anshuman P Malaviya,1 Andrew JK Östör1,21Rheumatology Clinical Research Unit, Addenbrooke's Hospital, Cambridge, UK; 2School of Clinical Medicine, University of Cambridge, Cambridge, UKAbstract: Major advances in drug development have led to the introduction of...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2012-08-01
|
| Series: | Patient Preference and Adherence |
| Online Access: | http://www.dovepress.com/drug-adherence-to-biologic-dmards-with-a-special-emphasis-on-the-benef-a10698 |
| _version_ | 1818701314820931584 |
|---|---|
| author | Malaviya AP Östör AJ |
| author_facet | Malaviya AP Östör AJ |
| author_sort | Malaviya AP |
| collection | DOAJ |
| description | Anshuman P Malaviya,1 Andrew JK Östör1,21Rheumatology Clinical Research Unit, Addenbrooke's Hospital, Cambridge, UK; 2School of Clinical Medicine, University of Cambridge, Cambridge, UKAbstract: Major advances in drug development have led to the introduction of biologic disease-modifying drugs for the treatment of rheumatoid arthritis, which has resulted in unprecedented improvement in outcomes for many patients. These agents have been found to be effective in reducing clinical signs and symptoms, improving radiological damage, quality of life, and functionality, and have also been found to have an acceptable safety profile. Despite this, drug adherence is unknown, which has huge health care and health-economic implications. Local and national guidelines exist for the use of biologics; however, its varied use is widespread. Although this may in part reflect differences in prescribing behavior, patient preference plays a key role. In this review we will explore the factors that contribute to patient preference for, and adherence to, biologic therapy for rheumatoid arthritis with emphasis on the subcutaneous preparation of abatacept, a T-cell costimulatory molecule blocker. Overall, subcutaneous administration is preferred by patients and this may well improve drug adherence.Keywords: subcutaneous administration, self-injectable, abatacept, rheumatoid arthritis, preference, adherence, compliance, biologic DMARD |
| first_indexed | 2024-12-17T15:18:53Z |
| format | Article |
| id | doaj.art-c03a0c1694ae4270af4438ea32f00c6e |
| institution | Directory Open Access Journal |
| issn | 1177-889X |
| language | English |
| last_indexed | 2024-12-17T15:18:53Z |
| publishDate | 2012-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Patient Preference and Adherence |
| spelling | doaj.art-c03a0c1694ae4270af4438ea32f00c6e2022-12-21T21:43:28ZengDove Medical PressPatient Preference and Adherence1177-889X2012-08-012012default589596Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abataceptMalaviya APÖstör AJAnshuman P Malaviya,1 Andrew JK Östör1,21Rheumatology Clinical Research Unit, Addenbrooke's Hospital, Cambridge, UK; 2School of Clinical Medicine, University of Cambridge, Cambridge, UKAbstract: Major advances in drug development have led to the introduction of biologic disease-modifying drugs for the treatment of rheumatoid arthritis, which has resulted in unprecedented improvement in outcomes for many patients. These agents have been found to be effective in reducing clinical signs and symptoms, improving radiological damage, quality of life, and functionality, and have also been found to have an acceptable safety profile. Despite this, drug adherence is unknown, which has huge health care and health-economic implications. Local and national guidelines exist for the use of biologics; however, its varied use is widespread. Although this may in part reflect differences in prescribing behavior, patient preference plays a key role. In this review we will explore the factors that contribute to patient preference for, and adherence to, biologic therapy for rheumatoid arthritis with emphasis on the subcutaneous preparation of abatacept, a T-cell costimulatory molecule blocker. Overall, subcutaneous administration is preferred by patients and this may well improve drug adherence.Keywords: subcutaneous administration, self-injectable, abatacept, rheumatoid arthritis, preference, adherence, compliance, biologic DMARDhttp://www.dovepress.com/drug-adherence-to-biologic-dmards-with-a-special-emphasis-on-the-benef-a10698 |
| spellingShingle | Malaviya AP Östör AJ Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept Patient Preference and Adherence |
| title | Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept |
| title_full | Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept |
| title_fullStr | Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept |
| title_full_unstemmed | Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept |
| title_short | Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept |
| title_sort | drug adherence to biologic dmards with a special emphasis on the benefits of subcutaneous abatacept |
| url | http://www.dovepress.com/drug-adherence-to-biologic-dmards-with-a-special-emphasis-on-the-benef-a10698 |
| work_keys_str_mv | AT malaviyaap drugadherencetobiologicdmardswithaspecialemphasisonthebenefitsofsubcutaneousabatacept AT ampoumlstampoumlraj drugadherencetobiologicdmardswithaspecialemphasisonthebenefitsofsubcutaneousabatacept |